121 related articles for article (PubMed ID: 35791470)
21. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations.
Pollock PM; Spurr N; Bishop T; Newton-Bishop J; Gruis N; van der Velden PA; Goldstein AM; Tucker MA; Foulkes WD; Barnhill R; Haber D; Fountain J; Hayward NK
Hum Mutat; 1998; 11(6):424-31. PubMed ID: 9603434
[TBL] [Abstract][Full Text] [Related]
22. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
23. [Increased knowledge on familial melanoma and the underlying genetics].
Helgadottir H; Nielsen K; Höiom V
Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
[TBL] [Abstract][Full Text] [Related]
24. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetics of familial cutaneous melanoma.
Haluska FG; Hodi FS
J Clin Oncol; 1998 Feb; 16(2):670-82. PubMed ID: 9469357
[TBL] [Abstract][Full Text] [Related]
26. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
[TBL] [Abstract][Full Text] [Related]
27. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.
Puig-Butille JA; Escámez MJ; Garcia-Garcia F; Tell-Marti G; Fabra À; Martínez-Santamaría L; Badenas C; Aguilera P; Pevida M; Dopazo J; del Río M; Puig S
Oncotarget; 2014 Mar; 5(6):1439-51. PubMed ID: 24742402
[TBL] [Abstract][Full Text] [Related]
28. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
[TBL] [Abstract][Full Text] [Related]
30. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
31. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
[TBL] [Abstract][Full Text] [Related]
32. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Burke LS; Hyland PL; Pfeiffer RM; Prescott J; Wheeler W; Mirabello L; Savage SA; Burdette L; Yeager M; Chanock S; De Vivo I; Tucker MA; Goldstein AM; Yang XR
PLoS One; 2013; 8(8):e71121. PubMed ID: 23990928
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
[TBL] [Abstract][Full Text] [Related]
34. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
de Torre C; Martínez-Escribano J
Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
[TBL] [Abstract][Full Text] [Related]
35. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
36. Cul4b Promotes Progression of Malignant Cutaneous Melanoma Patients by Regulating CDKN2A.
Zhang C; Cao C; Liu XL; Jun T; Liu P
Tohoku J Exp Med; 2021 May; 254(1):33-39. PubMed ID: 34011786
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of 9p21 deletions in UK melanoma families.
Mistry SH; Taylor C; Randerson-Moor JA; Harland M; Turner F; Barrett JH; Whitaker L; Jenkins RB; Knowles MA; Bishop JA; Bishop DT
Genes Chromosomes Cancer; 2005 Nov; 44(3):292-300. PubMed ID: 16032697
[TBL] [Abstract][Full Text] [Related]
38. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
39. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
DeLeon TT; Almquist DR; Kipp BR; Langlais BT; Mangold A; Winters JL; Kosiorek HE; Joseph RW; Dronca RS; Block MS; McWilliams RR; Kottschade LA; Rumilla KM; Voss JS; Seetharam M; Sekulic A; Markovic SN; Bryce AH
PLoS One; 2020; 15(3):e0230306. PubMed ID: 32196516
[TBL] [Abstract][Full Text] [Related]
40.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
